Publications (original articles or review articles) published in 2018 from OUS - Translational studies in solid tumors (Helland)
11 publications found
Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease
BMC Cancer, 18 (1), 739
DOI 10.1186/s12885-018-4659-0, PubMed 30005623
Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy
Adv Radiat Oncol, 3 (2), 130-138
DOI 10.1016/j.adro.2017.12.007, PubMed 29904737
Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study
J Thorac Oncol, 13 (12), 1906-1918
DOI 10.1016/j.jtho.2018.08.2027, PubMed 30217492
DNA Methylation of LRRC3B: A Biomarker for Survival of Early-Stage Non-Small Cell Lung Cancer Patients
Cancer Epidemiol Biomarkers Prev, 27 (12), 1527-1535
DOI 10.1158/1055-9965.EPI-18-0454, PubMed 30185536
Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab
Acta Oncol, 57 (9), 1225-1231
DOI 10.1080/0284186X.2018.1465585, PubMed 29683761
Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics
Oncoimmunology, 8 (2), e1537691
DOI 10.1080/2162402X.2018.1537691, PubMed 30713794
Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors
Mol Oncol, 12 (11), 1838-1855
DOI 10.1002/1878-0261.12375, PubMed 30133130
A multi-omic study reveals BTG2 as a reliable prognostic marker for early-stage non-small cell lung cancer
Mol Oncol, 12 (6), 913-924
DOI 10.1002/1878-0261.12204, PubMed 29656435
N-glycan signatures identified in tumor interstitial fluid and serum of breast cancer patients: association with tumor biology and clinical outcome
Mol Oncol, 12 (6), 972-990
DOI 10.1002/1878-0261.12312, PubMed 29698574
Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome
Br J Cancer, 118 (12), 1609-1616
DOI 10.1038/s41416-018-0115-9, PubMed 29872151
Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC
Clin Epigenetics, 10, 41
DOI 10.1186/s13148-018-0474-3, PubMed 29619118